Insider Trends: Insider at Emergent BioSolutions Acquires Stock Via Option/Derivative Security Sells Portion to Pay Tax, Buy Trend Intact
04:21 PM EDT, 05/11/2021 (MT Newswires) -- Dr Louis W Sullivan, Director, exercised options/derivative securities for 10,305 shares of Emergent BioSolutions (EBS) and sold 3,118 shares in the company for $192,131 to meet tax obligations on May 10, 2021. After accounting for tax obligations this transaction resulted in a net acquisition of 7,187 company shares. Following the Form 4 filing with the SEC, Dr Sullivan owns 39,945 shares of the company, with a market value, based on the prior-day closing price, of $2.39 million.
Over the last 90 days, previous to the date of this filing, there have been 17 insider transactions reported to the SEC for Emergent BioSolutions. These transactions came from the activities of 8 individual insiders that resulted in a net acquisition of 47,790 company shares. In the preceding 90-day window of time, there were 16 transactions from 5 insiders and resulted in the net disposition of 506 shares.
This level of insider transactions is lower than the peer group average in the 150-company Pharmaceuticals peer group over the last 90-day period. Activity in the peer group averaged 64.5 transactions per company, and disposition of 7,235 shares on average.
SEC Story Link http://www.sec.gov/Archives/edgar/data/1367644/000136764421000075/xslF345X03/wf-form4_162076428587593.xml
This report does not constitute a recommendation to purchase or sell any security and the analysts are not registered investment advisors. Further analysis is recommended before undertaking any position in any security. Any risks are solely the responsibility of the buyer/seller. The authors, publishers and distributors of the MT Newswires Live Briefs service and any associates thereof accept no liability for the content or actions taken by anyone or institution utilizing this report.